These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36072876)

  • 81. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry).
    Mennuni MG; Halperin JL; Bansilal S; Schoos MM; Theodoropoulos KN; Meelu OA; Sartori S; Giacoppo D; Bernelli C; Moreno PR; Krishnan P; Baber U; Lucarelli C; Dangas GD; Sharma SK; Kini AS; Tamburino C; Chieffo A; Colombo A; Presbitero P; Mehran R
    Am J Cardiol; 2015 Jul; 116(1):37-42. PubMed ID: 25956624
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Mishra A; Singh M; Acker WW; Kamboj S; Sporn D; Stapleton D; Kaluski E
    J Cardiovasc Pharmacol; 2019 Aug; 74(2):82-90. PubMed ID: 31306367
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery disease.
    Zheng YY; Wu TT; Guo QQ; Chen Y; Ma X; Ma YT; Zhang JY; Xie X
    Atherosclerosis; 2021 Jul; 328():1-10. PubMed ID: 34052667
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Antithrombotic strategies after transcatheter aortic valve implantation: Insights from a network meta-analysis.
    Kuno T; Takagi H; Sugiyama T; Ando T; Miyashita S; Valentin N; Shimada YJ; Kodaira M; Numasawa Y; Kanei Y; Hayashida K; Bangalore S
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):E177-E186. PubMed ID: 31609071
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
    Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    N Engl J Med; 2019 Sep; 381(12):1103-1113. PubMed ID: 31475793
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial.
    Smits PC; Frigoli E; Tijssen J; Jüni P; Vranckx P; Ozaki Y; Morice MC; Chevalier B; Onuma Y; Windecker S; Tonino PAL; Roffi M; Lesiak M; Mahfoud F; Bartunek J; Hildick-Smith D; Colombo A; Stankovic G; Iñiguez A; Schultz C; Kornowski R; Ong PJL; Alasnag M; Rodriguez AE; Moschovitis A; Laanmets P; Heg D; Valgimigli M;
    Circulation; 2021 Oct; 144(15):1196-1211. PubMed ID: 34455849
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Talib U; Nafee T; Daaboul Y; Pahlavani S; Pitliya A; Furqan MM; Datta S; Kazmi HA; Younes A; Gibson CM
    Prog Cardiovasc Dis; 2018; 60(4-5):524-530. PubMed ID: 29397950
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Cavallari I; Patti G
    Am J Cardiol; 2018 Mar; 121(6):718-724. PubMed ID: 29373105
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.
    Galli M; Andreotti F; Porto I; Crea F
    Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
    Vranckx P; Lewalter T; Valgimigli M; Tijssen JG; Reimitz PE; Eckardt L; Lanz HJ; Zierhut W; Smolnik R; Goette A
    Am Heart J; 2018 Feb; 196():105-112. PubMed ID: 29421002
    [TBL] [Abstract][Full Text] [Related]  

  • 93. D-dimer and fibrinogen indicate ischemic risk in patients with atrial fibrillation after percutaneous coronary intervention.
    Gjermeni D; Anfang V; Szabó S; Vetter H; Venhoff AC; Leggewie S; Hesselbarth D; Trenk D; Buechsel M; Westermann D; Olivier CB
    Thromb J; 2024 May; 22(1):42. PubMed ID: 38773510
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Risk Profiles and Treatment Patterns in Atrial Fibrillation Patients with Chronic Kidney Disease Receiving or not Receiving Anticoagulation Therapy.
    Kreutz R; Deray G; Floege J; Gwechenberger M; Hahn K; Luft AR; Persson P; Axthelm C; Beer JH; Bergler-Klein J; Lellouche N; Taggeselle J; Beyer-Westendorf J
    TH Open; 2024 Jan; 8(1):e106-e113. PubMed ID: 38406259
    [No Abstract]   [Full Text] [Related]  

  • 95. Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation.
    Lee SR; Rhee TM; Kang DY; Choi EK; Oh S; Lip GYH
    Am J Cardiol; 2019 Sep; 124(6):879-885. PubMed ID: 31311662
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention.
    Park J; Choi EK; Han KD; Kim B; Choi YJ; Lee SR; Kang J; Cha MJ; Park KW; Oh S; Lip GYH
    PLoS One; 2020; 15(10):e0240161. PubMed ID: 33057407
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Comparison of Efficacy and Safety of Anticoagulant Monotherapy and Combined Therapy of Anticoagulant and Antiplatelets in Patients With Stable Coronary Artery Disease and Atrial Fibrillation: A Meta-Analysis.
    Tentu N; Ijaz A; Batool S; Khan RS; Mohammed F; Khan MH; Sandhu QI; Ali N
    Cureus; 2022 Sep; 14(9):e29772. PubMed ID: 36324348
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease.
    Lee SR; Jung JH; Choi EK; Lee SW; Kwon S; Park JS; Kang J; Han KD; Park KW; Oh S; Lip GYH
    Front Cardiovasc Med; 2022; 9():991293. PubMed ID: 36072876
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.